Genmab traded at 2,353.00 this Monday July 4th, decreasing 8.00 or 0.34 percent since the previous trading session. Looking back, over the last four weeks, Genmab lost 10.68 percent. Over the last 12 months, its price fell by 9.19 percent. Looking ahead, we forecast Genmab to be priced at 2,271.05 by the end of this quarter and at 2,021.23 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Almirall SA 10.79 0.16 1.51% -27.92%
Amgen 245.55 2.25 0.92% -1.27%
Amarin 1.44 -0.05 -3.36% -67.20%
argenx SE 361.30 -1.40 -0.39% 40.31%
Artemis Alpha 296.54 -3.96 -1.32% -32.91%
AstraZeneca 10,808.00 54.00 0.50% 24.54%
Bayer 57.24 -0.11 -0.19% 11.30%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Exelixis 21.57 0.75 3.60% 18.13%
Fresenius Medical Care 47.66 0.08 0.17% -29.99%
Genmab 2,353.00 -8.00 -0.34% -9.19%
Galapagos 53.06 -1.04 -1.92% -8.30%
GN Store Nord 250.70 -8.30 -3.20% -55.39%
GRIFOLS 17.84 -0.80 -4.29% -19.44%
GlaxoSmithKline 1,802.60 17.00 0.95% 25.84%
Hikma Pharmaceutical 1,654.00 32.50 2.00% -34.78%
Immunogen 4.61 0.11 2.44% -28.30%
Insmed 20.89 1.17 5.93% -26.70%
Lonza Group 524.80 5.60 1.08% -19.93%
Merck 165.40 -0.30 -0.18% 1.26%
Novartis 81.65 1.32 1.64% -3.02%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Roche Holding 322.10 1.70 0.53% -8.06%
Sanofi 98.34 0.82 0.84% 13.16%
Seattle Genetics 180.11 3.17 1.79% 14.52%
UCB 82.64 0.04 0.05% -7.00%
William Demant Holding 268.20 -3.90 -1.43% -25.40%


Genmab
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.